Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

Takahashi, Hideaki; Tada, Yuichiro; Saotome, Takashi; Akazawa, Kohei; Ojiri, Hiroya; Fushimi, Chihiro; Masubuchi, Tatsuo; Matsuki, Takashi; Tani, Kaori; Yoshiyuki Osamura, R.; Hirai, Hideaki; Yamada, Shuhei; Kawakita, Daisuke; Miura, Kouki; Kamata, Shin-etsu; Nagao, Toshitaka

doi:10.1200/jco.18.00545

Public

Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

Published in Journal of Clinical Oncology • Nov 19, 2018

Authors:

Hideaki Takahashi

Yuichiro Tada

Takashi Saotome

Abstract

PURPOSE: Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's rarity. We assessed the efficacy and toxicity of trastuzumab plus docetaxel in patients with locally advanced and/or recurrent or metastatic h...

Subject

Medicine

Neutropenia

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!